Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells 5,556 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of CeriBell stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $22.60, for a total transaction of $125,565.60. Following the completion of the transaction, the vice president directly owned 18,900 shares in the company, valued at approximately $427,140. This represents a 22.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

David Foehr also recently made the following trade(s):

• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Performance

CBLL traded up $1.10 during trading on Wednesday, hitting $22.83. The stock had a trading volume of 677,591 shares, compared to its average volume of 435,769. The firm has a market cap of $846.99 million, a PE ratio of -15.12 and a beta of 1.02. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $26.04. The company has a 50 day simple moving average of $17.54 and a 200-day simple moving average of $15.03.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Trading of CeriBell

Several institutional investors have recently made changes to their positions in the business. CenterBook Partners LP increased its stake in CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after acquiring an additional 389,584 shares during the period. JPMorgan Chase & Co. grew its stake in shares of CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares during the period. Peregrine Capital Management LLC acquired a new position in shares of CeriBell in the 2nd quarter worth approximately $6,399,000. TimesSquare Capital Management LLC lifted its position in shares of CeriBell by 48.5% during the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after buying an additional 260,116 shares during the period. Finally, Millennium Management LLC boosted its stake in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after buying an additional 196,299 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have commented on CBLL shares. JPMorgan Chase & Co. dropped their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group upped their target price on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Monday, December 15th. Raymond James Financial initiated coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.